Rare diseases
Investigational molecules
Locations
Study on Long-term Safety of Nivolumab and Drug Combination for Cancer Patients from Previous BMS Trials
AustriaCevostamab, Pomalidomide and Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma Previously Treated with 1‑3 Lines of Therapy
CzechiaAccelerating improvement with teclistamab plus standard drug combination in newly diagnosed transplant‑eligible multiple myeloma patients
GermanyAZD0120 versus standard regimens in patients with relapsed or refractory multiple myeloma
FranceA study of etentamig and daratumumab compared to daratumumab, lenalidomide, and dexamethasone in adults with newly diagnosed multiple myeloma not eligible for transplant
FranceA study testing etentamig alone or with drug combinations in adult patients with multiple myeloma to assess safety and changes in disease activity
NorwayStudy of daratumumab, teclistamab and talquetamab combination treatment for frail patients with newly diagnosed multiple myeloma
ItalyStudy comparing daratumumab, lenalidomide and dexamethasone followed by linvoseltamab versus continued initial treatment in newly diagnosed multiple myeloma patients
AustriaStudy of ABBV-453 alone or with drug combination for adults with multiple myeloma: evaluation of safety and effectiveness
BelgiumStudy on Safe Skin Test Concentrations for Biotherapy Allergies in Patients with Cancer Using Atezolizumab, Daratumumab, and Nivolumab
FranceStudy on Daratumumab for Reducing Symptoms in Patients with Moderate to Severe Myalgic Encephalomyelitis/Chronic Fatigue Syndrome
NorwayStudy of elranatamab and lenalidomide combination versus standard chemotherapy and transplant in newly diagnosed multiple myeloma patients
BelgiumTell us about your condition – we search every trial in Europe and connect you with the right site.
